Traws Pharma, Inc. Segments Disclosure
10. Segment Information
The Company has one operating segment. The Company’s chief operating decision maker (“CODM”) is the chief executive officer. The Company’s CODM manages the Company’s operations on a consolidated basis for the purpose of allocating resources. All the Company’s long-lived assets are held in the United States.
The accounting policies of its segment are the same as those described in the summary of significant accounting policies. The CODM assesses performance for its segment based on net loss, which is reported on the consolidated statements of operations and comprehensive loss. The measure of segment assets is reported on the balance sheet as total assets. The CODM uses cash forecast models in deciding how to invest into the segment. The CODM analyzes the Company’s net loss and monitors budget versus actual results to assess the performance of the Company.
The table below summarizes the significant expense categories regularly reviewed by the CODM for the years ended December 31, 2024 and 2023:
Years ended December 31, | ||||||
| 2024 |
| 2023 | |||
Revenue | $ | 226,000 | $ | 226,000 | ||
Less: | ||||||
Acquired in-process research and development |
| 117,464,000 |
| — | ||
Research and development expenses: | ||||||
Preclinical & clinical development | 7,441,000 |
| 4,060,000 | |||
Personnel related | 2,787,000 |
| 2,400,000 | |||
Other research and development (a) | 2,619,000 |
| 4,970,000 | |||
Total research and development expenses |
| 12,847,000 |
| 11,430,000 | ||
General and administrative expenses: | ||||||
Professional & consulting fees | 5,954,000 |
| 2,162,000 | |||
Personnel related | 3,035,000 |
| 3,264,000 | |||
Other general and administrative (b) | 3,300,000 |
| 3,668,000 | |||
Total general and administrative | 12,289,000 | 9,094,000 | ||||
Series A warrant and pre-funded warrant expense | 24,438,000 | — | ||||
Other income, net |
| (289,000) |
| (1,350,000) | ||
Net loss | $ | (166,523,000) | $ | (18,948,000) | ||
About Segments Disclosures
Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.
Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.